🎮 Here's a mobile game you can't even start without a doctor's permission. Download it, tap the icon, and it asks for an activation code — the kind only a clinic can hand you. As of June 5, it became something stranger still: a game your Japanese health insurance will help pay for. And the twist gamers will appreciate most is that it runs on the very same technology that made history in the United States, then nearly took its maker down with it.

The game is called EndeavorRide, and the company behind its Japanese launch is Shionogi, one of the country's older pharmaceutical names. It is the first app Japan has ever approved as a "medical device program" — software that is regulated like a piece of medical equipment — to help treat ADHD in children. In other words, a video game with a label.

You steer it by tilting, and a clinic has to unlock it

Strip away the regulatory paperwork and EndeavorRide plays like a lot of casual mobile games. You tilt your phone or tablet left and right to move your character, while creatures drift in from the back of the screen and you tap to collect them. Doing both at once — steering and tapping — is the whole point. It's a "dual task," forcing your brain to juggle two streams of attention, and the difficulty is tuned to each individual player. There are daily missions, and the effect is meant to build with regular play, the way a training routine does.

Japanese TV coverage of the launch shows that gameplay in action:

Anyone can install it from the App Store. What you can't do is play. On launch, the game demands an activation code issued by a medical institution, which means the on-ramp isn't a credit card but a doctor's appointment. That single design choice tells you everything about what EndeavorRide is trying to be: not a wellness app you stumble onto, but a treatment a clinician decides to give you.

What the trial actually showed

The approval rests on a Phase 3 clinical trial — the large, decisive stage of human testing — run in Japan with 164 children aged 6 to 17 who were already receiving standard ADHD care, meaning environmental adjustments at home and school plus psychosocial therapy. The headline measure was the change in their inattention score on the ADHD-RS-IV, a widely used rating scale doctors fill out to gauge ADHD severity.

After six weeks, the group using EndeavorRide showed a statistically significant improvement over the group on usual care alone (p<0.05), and the trial met its main goal. Secondary measures, including total ADHD score and hyperactivity-impulsivity, moved in the same direction.

The mechanism, at least on paper, is Akili's SSME engine — short for Selective Stimulus Management Engine — which pairs sensory stimulation with simultaneous motor challenges to target the prefrontal cortex, the brain region that handles attention and impulse control. Worth keeping in perspective: the trial showed a measurable bump on an attention scale over a few weeks, not a cure, and Shionogi frames the app as an addition to existing treatment rather than a substitute for therapy or medication.

The American original that rose, then fell

None of this technology is new — and that's where the story gets interesting.

The engine inside EndeavorRide is the same one inside EndeavorRx, which launched in the US back in 2020 as the first prescription video game ever cleared by the Food and Drug Administration, for children aged 8 to 12 with ADHD. It went through a special regulatory route and effectively created a new category that the industry started calling "digital therapeutics." Its maker, a Boston startup called Akili, looked like the future. It went public in 2022 through a SPAC deal, raised roughly $163 million, and was briefly valued near $1 billion.

Then it hit a wall, and the wall was money. A doctor could prescribe EndeavorRx, but persuading American insurers to reimburse what looked, to them, like a phone game proved brutally hard. Akili pivoted toward an over-the-counter version for adults, cut about 40% of its staff in late 2023, and in 2024 was taken private by a company called Virtual Therapeutics for around $34 million — roughly 43 cents a share, a long fall from that billion-dollar peak. Akili now operates as a subsidiary out of Washington state. The game that broke new ground couldn't find a business model to stand on.

Why Japan's version has a different shot

Here is the part that makes the Japanese launch more than a footnote: the exact obstacle that strangled the product in America — getting someone to pay for it — is built into Japan's system from day one.

Japan runs universal public health insurance, and EndeavorRide enters as a prescription medical device covered by it. A patient who's prescribed the game pays only the usual out-of-pocket fraction, the same as for a normal doctor's visit, rather than the full sticker price. The friction in Japan isn't "will anyone reimburse this." It's access and gatekeeping: only clinics meeting specific facility and physician requirements, set under the 2026 fee revision, can prescribe it, and Japan's ADHD specialist society has published guidance on how to use it appropriately. That's a very different problem to have than the one that sank the US rollout.

It's a clean illustration of a quieter truth: a product can live or die less on whether it works than on the system it lands in.

The argument r/ADHD and r/gaming are about to have

You can already hear the threads forming. There's the screen-time paradox: prescribing more screen time to kids, some of whom are already wrestling with how much time they spend on devices. There's the eternal question of whether this is real medicine or gamified hope — it cleared a controlled trial, yes, but the effect lands on a specific attention measure, over a defined window, as a complement to other care.

And there's the part that's both the appeal and the catch: it's designed to be fun, because fun is what keeps a kid coming back day after day, which is exactly what a treatment needs and exactly what makes skeptics wary. EndeavorRide isn't pitched as a cure or a replacement; it's a narrow tool for childhood inattention, now sitting on a shelf next to therapy and medication.

A physician quoted in Japanese TV coverage framed the upside plainly: the point, the doctor said, is that families now have an option beyond medication and counseling.

In Japan, a doctor can now hand a child a code and say, in effect, "go play this — your insurance has it covered." Whether that's a glimpse of medicine's future or a clever way to bill for a game is the conversation worth having. Would your country's system cover a video game as treatment — and if it did, would you trust it?

References